



A VACCINE BREAKTHROUGH THAT WILL CHANGE LIVES

HOW WILL IT CHANGE YOUR PROGRAMS?

WHAT IF THERE WERE BETTER AND SAFER TREATMENTS FOR ALLERGY, CANCER OR ANIMAL HEALTH THAT WERE MORE EFFECTIVE THAN ANY VACCINE BEING DEVELOPED ON THE MARKET? WHAT IF YOU COULD GET IN ON THE GROUND FLOOR OF NEW, PATENTED TECHNOLOGY THAT IS ALREADY CHANGING THE VACCINATION GAME?

INTRODUCING LAMP-VAX™ TECHNOLOGY, A BREAKTHROUGH VACCINE PLATFORM THAT'S TRANSFORMING THE WAY RESEARCHERS BRING VACCINES TO MARKET.

LAMP-vax is a sequence added to nucleic acid vaccines to make them work more naturally and intuitively with the body's immune system. It diverts the synthesized protein products of DNA and RNA-based vaccines directly to the lysosome in the dendritic cells, making them readily available to form antigen-MHC-II complexes. These MHC-II complexes, after transport to the cell surface, directly interact with helper T-cells and lead to the production of antibodies & Th1 cytokines, while maintaining enhanced CD8+ cytotoxic T-cell activation.

The result is a greatly enhanced immune response that can promote positive clinical outcomes and ultimately enable effective and safer protection for patients.

LAMP may be the “missing link” to effective DNA and RNA vaccinations:

- Add to existing DNA or RNA nucleic acid formulations
- Resuscitate failed vaccine programs
- Add LAMP+DNA or LAMP+RNA prime to existing peptide or protein boost
- Reformulate a protein vaccine as a nucleic acid vaccine


Nucleic acid vaccines with LAMP have many advantages:

- Proprietary, intelligent design methodology
- Efficient and expeditious design and validation (3 months)
- Enhanced safety in allergy format
- Excellent stability with long shelf life
- Economical manufacturing cost
- Multivalent and multiplex capability


HUMANS



ALLERGY VACCINE THERAPY



ONCOLOGY IMMUNOTHERAPY




* Multi allergies represents 3-5 other allergy vaccines that Astellas will choose to develop under the license
 ** Animal development timeline not shown. 2 POC dog studies conducted to date

ANIMALS



ALLERGY



ONCOLOGY IMMUNOTHERAPY



INFECTIOUS DISEASE



ITI has a robust pipeline with several clinical and pre-clinical vaccines in internal development and access to options from Worldwide research laboratories. LAMP immunotherapies have been successfully used in Phase I and II clinical studies and have met their primary and secondary endpoints for safety, immunological and clinical responses for patients with prostate cancer, acute myeloid leukemia, melanoma and pollen allergy.

Contact us. Let us show you how LAMP-vax changes the game.